Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab
Cancers · 12.12.2025 · 17 (24) · 3971
DOI: 10.3390/cancers17243971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 12.12.2025. Verfasst von Yusuke Morita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatology, NHO Kyushu Cancer Center, Fukuoka 811-1395, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To evaluate the prognosis and costs of gemcitabine + cisplatin + S-1 (GCS) versus gemcitabine + cisplatin + durvalumab (GCD), the standard of care for advanced cholangiocarcinoma, in a prospective observational study.
Methods
We enrolled 52 patients who received GCS as first-line treatment from April 2020 to April 2024 and 44 patients who received GCD from March 2023 to April 2024. Overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) were examined. Propensity score matching (PSM) was performed to balance baseline characteristics between the two groups, and OS, PFS and ORR were then analysed in the matched cohorts. Drug costs were compared until the end of treatment.
Results
OS was not significantly different between GCS and GCD at 18.6 months (95% confidence interval [CI]: 13.3–21.9) (p = 0.0935) versus 12.2 months (95% CI: 7.5–16). PFS was 10.2 months (95% CI: 6.5–13.8) versus 6.2 months (95% CI: 3.2–8.8) for GCS versus GCD, respectively (p = 0.0151). The ORR was also higher for GCS (36.5%) than for GCD (15.9%) (p = 0.0234). Twenty-seven patients were included in the PSM analysis, which showed no significant differences in OS or ORR, and better PFS for GCS (9.3 months, 95% CI: 7.4–21.1 versus 4.8 months, 95% CI: 2.7–8.8; p = 0.007). The cost of GCS versus GCD was $6350 (95% CI: 2300–9800) versus $97,200 (95% CI: 69,400–138,800) by treatment end (p = 0.0001).
Conclusions
GCS was significantly less expensive than GCD and showed comparable OS and better PFS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatology, NHO Kyushu Cancer Center, Fukuoka 811-1395, Japan.
- Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
- Department of Hepatobiliary and Pancreatic Surgery, NHO Kyushu Cancer Center, Fukuoka 811-1395, Japan.
ORCID-Profile: Miho Kurokawa, Terumasa Hisano, Keishi Sugimachi
Zitieren
APA
Morita, Y., Sugimoto, R., Kurokawa, M., Tanaka, Y., Senju, T., Ichimaru, T., Lee, L., Niina, Y., Hisano, T., Furukawa, M., Sugimachi, K., & Tanaka, M. (2025). Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab. Cancers, 17(24), 3971. https://doi.org/10.3390/cancers17243971
Vancouver
Morita Y, Sugimoto R, Kurokawa M, Tanaka Y, Senju T, Ichimaru T, et al. Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab. Cancers. 2025;17(24):3971. doi:10.3390/cancers17243971
BibTeX
@article{Morita2025,
author = {Morita, Yusuke and Sugimoto, Rie and Kurokawa, Miho and Tanaka, Yuki and Senju, Takeshi and Ichimaru, Toshimitsu and Lee, Lingaku and Niina, Yusuke and Hisano, Terumasa and Furukawa, Masayuki and Sugimachi, Keishi and Tanaka, Masatake},
title = {Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab},
journal = {Cancers},
year = {2025},
volume = {17},
number = {24},
pages = {3971},
doi = {10.3390/cancers17243971}
}
EUVIMED